Selected Clinical and Demographic Data on Patients Imaged in This Study
Patient no. | Age (y) | Prostate-specific antigen (ng/mL) | Serum folate (ng/mL; normal, 2.5–20) | Red cell folate (ng/mL; normal, 160–855) | Testosterone (ng/dL) | Prior prostate cancer therapy |
1 | 72 | 81.8 | >24 | 478 | <20 | Prostatectomy, external-beam radiation to the pelvis, androgen deprivation |
2 | 83 | 11.6 | 14.6 | 429 | 245 | External-beam radiation to the pelvis |
3 | 61 | 38.9 | >24 | 559 | <20 | External-beam radiation to the pelvis, androgen deprivation |
4 | 70 | 8.3 | 12 | 268 | 247 | Prostatectomy |
5 | 68 | 67.6 | 13.6 | 361 | 465 | None |
6 | 76 | 31.4 | >24 | 627 | <20 | Prostatectomy, androgen deprivation |
7 | 59 | 99.6 | >24 | 433 | <20 | Androgen deprivation, docetaxel, external-beam radiation to the spine |
8 | 69 | 95.8 | 18.1 | 486 | <20 | External-beam radiation to the pelvis, androgen deprivation |
9 | 69 | 6.7 | 17.1 | 359 | <20 | Androgen deprivation |
10 | 61 | 48.3 | 16.6 | NA | 331 | Prostatectomy, external-beam radiation to the pelvis |
11 | 73 | 98.8 | >24 | NA | 280 | Prostatectomy |
12 | 62 | 564.5 | 11.8 | NA | <20 | Androgen deprivation, docetaxel, tasquinimod, external-beam radiation to the right hip, 223Ra |
13 | 55 | 62.1 | 10.3 | NA | 442 | Prostatectomy |
14 | 58 | 3.5 | 11.8 | 584 | 273 | Prostatectomy, external-beam radiation to the pelvis |
15 | 77 | 316.1 | 14.2 | 860 | <20 | Androgen deprivation, abiraterone |
16 | 75 | 6.7 | 10.4 | 666 | 746 | Prostate brachytherapy |
17 | 75 | 83.6 | 22 | 1049 | 538 | External-beam radiation to the pelvis |
NA = not available.